Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

• Published in: Clinical cancer research Vol. 15; no. 1; pp. 355 - 360
• Main Authors: Treon, Steven P, Soumerai, Jacob D, Branagan, Andrew R, Hunter, Zachary R, Patterson, Christopher J, Ioakimidis, Leukothea, Chu, Luis, Musto, Paul, Baron, Ari D, Nunnink, Johannes C, Kash, Joseph J, Terjanian, Terenig O, Hyman, Paul M, Nawfel, Elena L, Sharon, David J, Munshi, Nikhil C, Anderson, Kenneth C
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.01.2009
• Subjects: Aged; Aged, 80 and over; Anemia - chemically induced; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Drug Administration Schedule; Female; Humans; Immunoglobulin M - blood; lenalidomide; Male; Middle Aged; Neutropenia - chemically induced; Rituximab; Thalidomide - administration & dosage; Thalidomide - adverse effects; Thalidomide - analogs & derivatives; Thrombocytopenia - chemically induced; Waldenstrom Macroglobulinemia - drug therapy; Waldenstrom's macroglobulinemia
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-08-0862

Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent. Experimental Design: Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m 2 /wk) dosed on weeks 2 to 5 and 13 to 16. Sixteen patients were enrolled, 12 of whom were previously untreated. Results: Unexpectedly, we observed an acute decrease in hematocrit in 13 of 16 patients (median hematocrit decrease, 4.8%), which was attributable to lenalidomide patients and which led to cessation of further enrollment on this study. Lenalidomide-related anemia was observed even at doses as low as 5 mg/d and occurred in the absence of hemolysis or other cytopenias. The overall response and major response (<50% decrease in serum IgM) rates were 50% and 25%, respectively, on an intent-to-treat basis. With a median follow-up of 31.3 months, 4 of 8 responding patients have progressed with a median time to progression of 18.9 months. Conclusion: Lenalidomide produces unexpected but clinically significant acute anemia in patients with WM. In comparison with our previous study with thalidomide and rituximab in an analogous patient population, the responses achieved in WM patients with lenalidomide and rituximab appear less favorable.